Influence of Valsartan or Olmesartan on renin-angiotensin-aldosterone system and left ventricular remodeling after cardiac surgery

Influence of Valsartan or Olmesartan on renin-angiotensin-aldosterone system and left ventricular remodeling after cardiac surgery - Influence of Valsartan or Olmesartan on renin-angiotensin-aldosterone system and left ventricular remodeling after cardiac surgery

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000001465

Enrollment

200

Registered

2008-10-29

Start date

2004-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

myocardial infarction, angina

Interventions

postoperative administration Valsartene postoperative administration Olmesartan postoperative non-administration of Valsartene or Olmesartan

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patient undergoing CABG Patients from whom informed consent was obtained

Exclusion criteria

Exclusion criteria: preoperativerenal impairment(Cr>1.3mg/dl) preoperative cardiogenic shock

Design outcomes

Primary

Measure	Time frame
long-term result cardiac event	—

Secondary

Measure	Time frame
UCG (EF, LVDd, LVDs) BNP renin, angiotensin, aldosterone	—

Countries

Japan

Contacts

Public ContactAkira Sezai

Nihon University School of Medicine Department of Cardiovascular Surgery

asezai.med@gmail.com03-3972-8111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026